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Bone regenerationAspiration of iliac crest bone marrow (ICBM) remains the most frequent technique used in harvesting
multipotential stromal cells (MSCs) for bone regeneration. Although this tissue type is easily accessed by a
surgeon, it has a low frequency of MSCs, which is signiﬁcant given the high cell numbers required for bone
regeneration strategies. Lipoaspirates possess higher MSC frequencies, albeit cells with a differentiation
proﬁle less suited to orthopaedic interventions. Intra-medullary cavities of long bones have previously been
shown to harbour MSCs in animals, however evaluation of their frequency, differentiation capacity and
phenotype in humans had not previously been performed.
Long bone fatty bone marrow (LBFBM) was collected prior to harvesting bone graft. Basic cellular
compositions of donor-matched LBFBM and ICBM aspirates, including the numbers of CD34+ hematopoietic
stem cells and CD31+ endothelial cells, were similar. MSCs were enumerated using colony-forming-unit-
ﬁbroblast assays and ﬂow cytometry for the presence of a resident LBFBM CD45−/low CD271+MSC population
and revealed a trend for higher MSC numbers (average 5 fold, n=6) per millilitre of LBFBM compared to
donor-matched ICBM. Functional characteristics of resident MSCs, including their growth rates, differenti-
ation potentials and surface phenotypes (CD73+CD105+CD90+) before and after culture-ampliﬁcation,
were similar. Enhanced numbers of MSCs could be recovered following brief enzymatic treatment of solid
fragments of LBFBM.
Our ﬁndings therefore reveal that the intramedullary cavity of the human femur is a depot of MSCs, which,
although closely associated with fat, have a differentiation proﬁle equivalent to ICBM. This anatomical site is
frequently accessed by the orthopaedic/trauma surgeon and aspiration of the intramedullary cavity represents a
‘low-tech’ method of harvesting potentially large numbers of MSCs for regenerative therapies and research.
This article is part of a Special Issue entitled: Interactions Between Bone, Adipose Tissue and Metabolism.usculoskeletal Diseases, Leeds
ilding, St James's University
3438502.
 license.© 2011 Elsevier Inc. Open access under CC BY license.Introduction
The iliac crest bone marrow aspirate (ICBMA) was the ﬁrst source
from which multipotential stromal cells (MSCs), also termed mesen-
chymal stemcells,were isolated [1]. This anatomical sitehas become the
most frequently accessed in harvesting MSCs for bone tissue engineer-
ing and is generally accepted as the ‘gold-standard’.Whilst this source is
readily accessible and has good handling properties it has a low
frequency of MSCs (0.001–0.01%) [1]. This is of signiﬁcance as many
regenerative medicine uses of MSCs including putative bone repairapplications require large cell numbers [2–4]. High MSC yields can be
achieved by in vitro culturewith relative ease, with a 1000-fold increase
innumberswithin 2–3 weeks [5]. However, this results indaughter cells
that have reduced differentiation capacity [5] and impaired cell function
includinggradual accumulation of senescence-relatedmarkers [6,7] and
increased potential for transformation [8]. This process is also time-
inefﬁcient, expensive and requires industrial-scale good-manufacturing
practice (GMP)-compatible cell expansion facilities and a two-stage
surgery for tissue procurement and implantation [9].
Due to these factors there is a need to ﬁnd alternative MSC sources
where there is a potentially larger yieldof cells. Initial techniques involved
the development of devices to concentrate MSCs from large volumes of
ICBM aspirate by centrifugation [10]— and such devices are available in
the clinic. The implantation of 50,000 uncultured MSCs/CFU-Fs by
concentrating up to 300 ml of ICBMA has shown an improvement of
fracture healing in one study [10]. However, it is not always possible to
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rich connective tissues such as fat has been proposed as an alternative
strategy,with authors reporting the liberation of 500-foldmoreMSCs per
gram of tissuewhen comparedwith ICBMA [11]. Lipoaspiration however
cannot be performed for every orthopedic patient and the “quality” of
lipoaspirate-derivedMSCs for bone repair applications remains debatable
[12–17].
Multipotential stromal cells have previously been shown to be
present in the intramedullary cavity of long bones in humans [18].
However, this has been largely ignored as a source of MSCs for bone
regeneration. In contrast, the harvesting of long-bone BM has been
practiced on rat [19], mouse [20], rabbit [21–23] and pig [24,25] and is
probably the most prevalent research method of isolating MSCs from
animals. Analogous to other adipose-rich tissues, it may be hypoth-
esized that the intra-medullary (IM) contents of long bones contain
large numbers of MSCs. Unlike peripheral fat tissues, the MSCs are
present in a bone related micro-environment and may potentially
exhibit good intrinsic osteogenic capabilities. This is supported by
early pioneering ﬁndings documenting a strong in vivo osteogenic
capacity of adipogenic marrow cells [23].
This study explored the aspirated contents from the IM cavities of
long bones, which are frequently accessed by the trauma/orthopaedic
surgeon, as a source of MSCs in comparison to the ‘gold standard’ iliac
crest aspirated source.We used colony-forming ﬁbroblast (CFU-F) assay
[26] and ﬂow cytometry for CD45−/lowCD271+ fraction [27–29] to
enumerate MSCs and compared their frequency with donor-matched
ICBMaspirates.Wealsoused functional in vitroassays forMSCexpansion
and differentiation, to demonstrate that MSCs from IM cavities of long
bones were equal or superior to their ICBMA counterparts. These
ﬁndings should permit the development of novel one-step MSC
harvesting procedures for bone repair augmentation in fracture patients.Materials and methods
Subjects and specimen collection
Approval for these studies was obtained from the Leeds Teaching
HospitalNHS trust ethics committee,withall patientsproviding informed
consent. For the purpose of this research, iliac crest bonemarrowaspirate
(ICBMA) was obtained from 11 acute trauma patients, 11 patients with
post-traumatic disorders, 15 patients with long bone (tibia/femur) non-
union fractures and 6 healthy controls (Table 1). Sampleswere harvested
from patients during operation; ICBMA (10 ml) was aspirated from the
anterior iliac crest, using an 11-gauge, bevel-tipped trocar (Stryker,
Kalamazoo, Michigan, US) and 10 ml syringe (BD Biosciences, Oxford,
UK). Donor-matched ICBMA and LBFBM material was collected from
8 patientswith non-union fractures (median age 35 years, range 19–65).
The LBFBM contents were aspirated via the greater trochanter,
whichwas opened surgically, prior to the harvest of bone graft using theTable 1
Characteristics of patients participating in this study.
Patient group Diagnosis Procedure
Acute trauma (n=11) Fracture of pelvis (n=10)
Fracture of tibial plateau (n=1)
Open reduction and in
ﬁxation (n=11)
Post-traumatic disorders
(n=11)
Post traumatic sacroiliac joint
instability (n=2) Other (n=9)a
Injection (n=2) Rem
metal (n=2) Otherb (
Established atrophic
non-union (n=15)
Fracture non-union (femur, n=9,
tibia, n=6)
Reamer-Irrigator aspir
Normal controls (n=6) NA ICBM harvest for allog
transplant
NA — not applicable.
a Include post traumatic heterotrophic bone formation, infection, meniscal injury, and co
b Include excision, debridement, and arthroscopy.reamer–irrigator–aspirator (RIA) (Synthes, Westchester, Pennsylvania,
USA) for the grafting of non-unions [30]. Following the operative
opening of this cavity, via the greater trochanter, suction tubing and
50ml bladder syringe was used to collect the sample. In some patients
with fracture non-union 10 ml of peripheral blood (PB) was also
collected (n=5). Samples were transferred immediately into EDTA
containing vacutainers (BD Biosciences) and transported to the
laboratory.
Specimen processing
Samples were processed under aseptic conditions and sample
volumes in millilitres were recorded. The average sample volume for
long bone fatty bone marrow aspirate was 12 ml (range 11–17 ml);
ICBM aspirate volume was always 10 ml. A manual nucleated cell
(NC) count was performed on every sample following red cell lysis in
4% acetic acid (Sigma, Gillingham, UK). In some experiments (n=4),
the aspirated IM contents were left at room temperature for 1 h,
during which the fatty contents congealed leading to the formation of
‘solid’ and ‘liquid’ phases. To physically separate these phases,
samples were passed through a 70 μm cell strainer (BD Biosciences).
The resulting solid phase was digested using collagenase (Stem Cell
Technologies, Grenoble, France) at 1:1 ratio w/v (ﬁnal concentra-
tion=0.125%), for 60 min at 37 °C. Subsequently all fractions were
used for CFU-F assay or initiation of in vitro MSC cultures. In some
experiments (n=7), mononuclear cells (MNCs) were isolated using
Lymphoprep (Axis-shield, Huntingdon, UK) and counted, as described
previously [27].
CFU-F assay and MSC expansion
CFU-F assay was performed as previously described [26] with
minor modiﬁcations. Brieﬂy, 100 μl or 200 μl of each sample (200 μl or
400 μl of the matched FBM-solid fraction to account for dilution with
collagenase) was directly plated into a 10 cm diameter petri-dish
(Corning Life Sciences, Amsterdam, Holland) with 15 ml of non-
haematopoietic media (Miltenyi Biotec, Bisley, UK) in duplicate. Cells
were allowed 48 h to adhere, after which red blood cells and other
non-adherent cells were removed with two washes of phosphate
buffered saline (PBS) (Invitrogen, Paisley, UK). Adherent cells were
cultured (37 °C, 5% CO2) with half-media changes performed twice
weekly. PB MNCs were seeded at 5×106 cell/dish and cultured
similarly [31]. Crystal violet staining was performed on the fourteenth
day, as previously described [32] before scoring blindly.
Expansion was performed to produce sufﬁcient cells to undertake
trilineage differentiation and cell surface phenotyping in all fractions
as previously described [32]. Cells were expanded until 80%
conﬂuency was attained (denoted as passage 0/P0), after which
cells were trypsinised and passaged up to P3 [32,33]. PopulationTime of procedure after
initial injury, median (range)
Age, years,
median (range)
CFU-F/ml of ICBMA,
median (range)
ternal 3 days (0–10 days) 42 (21–72) 48 (11–1500)
oval of
n=7)
3 months (1–48 months) 33 (18–67) 90 (6–1445)
ation 18 months (6–72 months) 39 (19–65) 139 (8–2110)
eneic NA 35.5 (19–58) 148 (48–1943)
ccydynia.
512 G. Cox et al. / Bone 50 (2012) 510–517doublings (PDs) were calculated according to the following formula:
PDs=log2(N total cells /Total CFU-F on day 0) [33].
Tri-lineage differentiation
Passage-3 MSCs (n=4 donors) were induced towards osteogenesis,
chondrogenesis and adipogenesis according to standardprotocols [1,32].
For osteogenesis, cells were seeded at a density of 3×104/well in 3 cm
diameter wells (Corning Life Sciences) and cultured in low glucose
DMEM with 10% FCS, supplemented with standard antibiotic mixture
(100 U/ml penicillin and 100 μg/ml streptomycin) (all from Invitrogen),
100 nM dexamethasone, 10 mM β-glycerophosphate and 0.05 mM
ascorbic acid (all from Sigma), with twice weekly half-media changes.
Alkaline phosphotase activity was assessed on day 14 post-induction, as
previously described [32]. For adipogenesis, cellswere seeded in 12-well
plates at 1×105 cells/well and cultured in low glucose DMEMwith 10%
FCS, antibiotics, 10% horse serum (Stem Cell Technologies), 0.5 mM
isobutylmethylxanthine, 60 μM indomethacin and 0.5 μM hydrocorti-
sone (all from Sigma). Cultures were stained on day 14 post-induction
with Oil-Red-O, as previously described [27,32].
A 3D pellet culture model was used to induce chondrogenesis as
previously described [32]withminormodiﬁcations. Brieﬂy, pelletswere
formed in1.5 mlmicro-centrifuge tubes by centrifugation (650 g, 5 min)
of 2.5×105 cells suspended in 1 ml of serum-free medium consisting of
high glucoseDMEM(Invitrogen), antibiotics, 40 μg/ml L-proline, 1.5 mg/
ml BSA, 4.7 μg/ml linoleic acid, 1× insulin–transferrin–selenium, 50 μg/
ml L-ascorbic acid-2-phosphate, 100 nM dexamethasone (all from
Sigma) and 10 ng/ml TGF-β3 (R&D Systems, Abbingdon, UK). Full
media changes were performed twice weekly and biochemical assess-
ment performed at 21 days as previously described [34] with minor
modiﬁcations. Brieﬂy, pellets were digested for 18 h at 60 °C, with a
papain digestion solution containing 100mM Sodium Phosphate Buffer
supplementedwith 5 mMNa2EDTA, 10 mML-cysteine and0.125 mg/ml
papain (all from Sigma). DNA content was assessed using a Quant-iT™
PicoGreen® dsDNA Reagent Kit (Invitrogen) and produced glycosami-
noglycan (GAG) was measured using a Blyscan™ kit (Biocolor Life
Sciences, Co Antrim, Ireland).
Surface phenotype of culture expanded MSCs
Passage-3 MSCs (n=3 donors) were trypsinised and re-suspended
at 107 cells per ml in FACS buffer (PBS+0.5% BSA) before surface
staining with CD45 (Leukocyte Common Anigen)-PE-Cy7, CD34
(gp105–120)-PerCp (BD Biosciences), CD271 (Nerve growth factor
receptor)-APC (Miltenyi Biotec), and a pair of FITC- and PE-labelled
antibodies, including: CD31(PECAM-1)-FITC (Serotec, Kidlington, UK),
CD33 (gp67)-FITC, CD61 (Integrin β3)-FITC, CD73 (5′ Ecto-nucleotid-
ase)-PE , CD19-PE (BD Biosciences), CD105 (Endoglin)-PE and CD90
(Thy1)-PE (Serotec). All antibodies were used at the manufacturers'
recommended concentrations with matched isotype controls (from
Serotec). Dead/dying cells were excluded from the analysis using DAPI
(Sigma) andwere normally less than 5%. Datawere analysed on an LSRII
ﬂow cytometer equipped with DIVA software (BD Biosciences).
MSC enumeration
The phenotypic identiﬁcation of the ‘ex-vivo MSC’ using the
CD45−/lowCD271+ phenotype was ﬁrst described by our group using
ICBMA [27,28,35] and has since been independently validated by others
[29,36,37]. MSC enumeration was performed by staining the aspirated
MNC fractionwith CD45-FITC (DakoUKLtd, Ely, UK), CD271-PE (Miltenyi
Biotec) and 7-AAD, as previously described [28]. A minimum of 5×105
events were acquired and analysed using an LSRII ﬂow cytometer to
establish the percentage of CD45−/lowCD271+ cells. The frequency of
CD45−/lowCD271+ per ml of sample was then calculated based on thefollowing formula: CD45−/lowCD271+ cells/ml=% CD45−/lowCD271+
cells×MNCs/ml.
Extended phenotypic analysis of ‘ex-vivo MSC’ using 6-colour ﬂow
cytometry
Bone marrow MNCs were isolated using Lymphoprep and cells
were then re-suspended at 1×107 cells/ml in FACs buffer. Antibodies
were added at the manufacturers' recommended concentrations and
the cells were incubated for 20 min. Antibodies used were: CD45-
PECy7, CD73-PE, CD34-PerCP, CD19-PE, CD33-FITC, CD61-FITC (BD
Biosciences), CD90-PE, CD105-PE, CD31-FITC (Serotec) and CD271-
APC (Miltenyi Biotec). The cells were washed and re-suspended in
FACs buffer containing 100 ng/ml DAPI before analysing on an LSRII
ﬂow cytometer. Dead cells were excluded from the analysis using
DAPI (usually b5%) before gating on the CD45−/low CD271+ cell
population and assessing the expression of all other markers.
Statistics
Statistical analysis and graphing were performed using GraphPad
Prism version 4 for Windows (San Diego, California, USA). Gaussian
distribution could not be assumed given the number of samples and
differences between donor-matched ICBMA and LBFBM groups were
tested using Wilcoxon signed ranks test. The differences in the MSC
content between different patient groups were analysed using Mann–
Whitney test. Signiﬁcance was assumed when pb0.05.
Results
Basic cellular characterisation of ICBM and LBFBM aspirates
A standard CFU-F assay was ﬁrst performed to measure the MSC
content of ICBM aspirates in three groups of orthopaedic patients and
healthy controls (Table 1). Consistent with previously reported ﬁndings
[10], high donor-to-donor variation was observed, potentially due to
factors related to donor age [38] or a variable degree of dilution of ICBM
sample with blood during the aspiration procedure [39]. No signiﬁcant
differences in CFU-F abundance in ICBMAwere found between all three
groups of orthopaedic patients and healthy controls (Table 1). A ﬂow
cytometry-based ‘instant’ enumeration of MSCs was additionally
performed based on their CD45−/lowCD271+ phenotype. Consistent
with our previous data [28], direct positive correlation was observed
between the numbers of CFU-Fs and CD45−/lowCD271+ cells per ml of
ICBMA (r=0.700, p=0.013, n=13). These data conﬁrmed a possibility
of usingﬂowcytometry for enumeratingMSCs in othermarrowsources,
including LBFBM aspirates.
The analysis of different hematopoietic and non-hematopoietic cell
types in ICBMand LBFBMaspirateswasﬁrst performed to compare their
basic cellular composition (Fig. 1). The cellularity (both as total NC and
MNC counts) of LBFBM aspirates was similar to donor-matched ICBM
aspirates (Figs. 1A and B). The majority of cells in both tissues were
CD45+ leukocytes, including CD19+ B-cells, CD33+ myeloid cells and
CD61+ megakariocytes/platelets (Figs. 1C and D). Similar to other cell
types, the numbers of cells with pro-healing capabilities: CD34+
hematopoietic progenitor cells and CD31+ endothelial/angiogenic
cells [40] were not statistically different between the two sources
(Figs. 1C and D).
ResidentMSCsweremeasured using CFU-F assay and ﬂow cytometry
for the CD45−/lowCD271+ cell population (Figs. 1E–I). The frequency
of CD45low CD271+ cells was higher in LBFBM aspirate (Fig. 1E). In
correspondence, LBFBM aspirate contained higher numbers of CFU-Fs
compared to ICBMA(medianvalues 293 and115 CFU-F/ml, respectively),
however differences narrowly failed to reach statistical signiﬁcance
(p=0.0515, Fig. 1F). CFU-Fdishes froma representative donor are shown
on Fig. 1G. A similar trend for the MSC increase in LBFBMAwas observed
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numbersof colonies in LBFBM. I—Total numbersof CD45−/lowCD271+cells perml.H— Flow
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Flow cytometry data froma representative donor are shown in Fig. 1I. It is
noteworthy, that no CFU-Fs/MSCs were found in PB of patients with
fracture non-unions (n=5). Based on these ﬁndings it is evident that
LBFBMaspirateswere not inferior to ICBMA in termsof the proportions of
regenerative cells and MSCs per sample volume.Extended phenotypic characterisation of uncultured MSCs in LBFBM
aspirates
Although MSCs were found in similar proportions in LBFBM and
ICBM aspirates, their functional and phenotypic characteristics could
be altered in fatty environments. An extended phenotypic analysis of
CD45−/lowCD271+ ‘ex vivo’ MSCs in LBFBM and ICBM aspirates was
undertaken to identify any potential differences in surface receptor
expression. The gating strategy for this analysis is shown in Fig. 2A.
CD73 (5′ Ecto-nucleotidase) is a broadly-accepted MSC marker [1,39]
and it was expressed at similar levels on CD45−/lowCD271+ ‘ex vivo’
MSCs from both sources (~91%, n=3) (Fig. 2B). The MSC markers
CD105 (Endolgin) and CD90 (Thy1) were expressed at similar levels
in LBFBM and ICBM aspirates (Fig. 2B) whereas CD31 (PECAM-1), an
endothelial cell marker, was negative. Finally, we investigated the
expression of CD34 molecule on MSCs from ICBMA and LBFBM. This
was based on recently-published evidence of CD34 being present on
MSCs from lipoaspirates [41]. Consistent with our previous ﬁndings
relating to ICBMA [27], CD34 was absent on CD45−/low CD271+ MSCs
from both bone sources (Fig. 2B). Overall, MSC marker expression
levels were similar in LBFBM and ICBM aspirates and representative
marker histograms are shown on Fig. 2C. Therefore, based on the
expression of 5 selected surface markers, CD45−/low CD271+ cells
from LBFBM aspirates had classical ‘ex vivo’ BM MSC phenotype,
similar to ICBMA and different from lipoaspirates.
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ICBM aspirates
Although MSC numbers and phenotypes were similar in ICBM and
LBFBM aspirates, functional differences in MSCs could exist, due to their
anatomical locations. We next compared growth and phenotypic
characteristics of MSC cultures obtained from LBFBM and ICBM aspirates
(Fig. 3).
No statistically signiﬁcant differences were found in the growth
rates, measured as days/PD up to P3, of ICBMA and LBFBM derived MSC
cultures (median values of 2.36 and 2.44, respectively, Fig. 3A). Early-
passage cultures (P3) from both sources had indistinguishable mor-
phology (Fig. 3B) and similar phenotypes, using an extended panel of 10
surface markers (Fig. 3C). The majority of cultured cells expressed MSC
markers CD73, CD90 and CD105 and were negative for hematopoietic
lineage cell markers as well as CD31 and CD34. Representative
histograms are shown on Fig. 3D. Altogether these data showed that
LBFBMaspirateswere similar to donor-matched ICBMaspirates in terms
of growth and phenotypic characteristics of resident MSCs.
Differentiation potentials of MSCs derived from LBFBM and ICBM
aspirates
To investigate tripotentiality, P3-MSC cultures derived from ICBM
and LBFBM aspirates were placed in osteo-, adipo- and chondrogenic
differentiation conditions (n=4 donors)(Fig. 4). All cultures exposed
to osteogenic induction conditions for 14 days contained polygonalD
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(n=3matcheddonors, error bars represent SDs). D—Histograms showing theexpression
of markers on MSCs cultured from ICBMA (white) and LBFBM (grey) from one
representative donor. Dotted lines show isotype control.
the pellet was calculated.cells consistent with osteoblastic progression (Fig. 4A). No obvious
pattern of differences between ICBM and LBFBM aspirates was
documented in the proportions of alkaline-phosphatase positive
cells (Fig. 4B). Similar data were obtained for adipogenesis: all MSCs
were able to produce Oil-Red positive mature adipocytes, with no
apparent gross differences between the samples (Figs. 4C and D).
Chondrogenesis was performed using a classical pellet culture [27] and
measured as accumulation of cartilage-speciﬁc proteoglycans per cell
[34]. Similarly to osteo- and adipogenesis, no signiﬁcant differences
between ICBM- and LBFBM-derived pellets were found (Figs. 4E–G).
We next investigated whether any observed donor-to-donor
differences could be attributed to the “in vitro age” of tested cultures
(measured as total PDs at P3, i.e. prior to differentiation). On average,
MSCs from ICBM aspirates and LBFBM aspirates have both undergone
16PDs, with no apparent correlations being found between the “in
vitro age” and functional outcomes for individual cultures. Overall, all
these functional data showed that LBFBM MSCs were osteogenic and
chondrogenic at the levels comparable, and often superior, to ICBM
MSCs, making them suitable for therapeutic bone repair applications.
Enhanced release of MSCs from LBFBM aspirates using an enzymatic
digestion technique
Following 1-hour storage at RT, fatty components of LBFBM
aspirates tend to congeal, resulting in the formation of fatty solid
aggregates. To extract increased numbers of MSCs from this material,
the solid aggregates from LBFBM aspirates were exposed to a brief
enzymatic digestion (Fig. 5).
Although a trend for higher numbers of CFU-F/ml was found in the
solid phase (Figs. 5A and B), the differences were not statistically
different between liquid and solid phases. Similar ﬁndings were
observed for percentages of CD45−/lowCD271+ cells (Figs. 5C and D).
Fatty solid aggregates contributed to ~23% of total sample volume
(Fig. 5E) and contained the equivalent of ~30% of the total sample's
CFU-Fs (Fig. 5F). At room temperature theseMSCs are “trapped” in the
solid fatty aggregate, but were easily released by a brief enzymatic
digestion. Alternatively, samples could be kept at body temperature
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solidiﬁcation of fatty components.
Discussion
The conversion of red marrow to yellowmarrow is a physiologically
dynamic process that starts in infancy at the terminal phalanges and
progresses in a centripetal direction [42], so that by adulthood the
diaphyses of long-bones are almost entirely populated by yellow, fatty
bone marrow [43]. MSCs are commonly harvested from long-bones in
rat [19], mouse [20], rabbit [21,23] and porcine [24,25] models. In
contrast to human subjects, the description of a yellow fatty appearance
of the longbonemarrow in these reports is rarelymentioned,whichmay
be partly due to the fact that themajority of animalmodels are sacriﬁced
at a juvenile stage— possibly prior to redmarrow conversion. The aim of
this study was to comprehensively assess human LBFBM as a source of
MSCs for bone repair applications and to compare it with ICBM aspirate.
Using donor-matched samples, we have found that LBFBMwas non-
inferior to ICBMA in terms of its cellularity, basic cellular composition
and the proportions of MSCs. In fact, LBFBM had higher proportions of
CFU-Fs compared to ICBMA (2.5-fold). These differences narrowly failed
to reach statistical signiﬁcance but in a larger scale study theymaydo so.
Despite the fatty environment within LBFBM cavity, LBFBM-derived
MSCs possessed the classical MSC phenotype, before and after culture,
arguing for good preservation of their undifferentiated status. Further-
more, LBFBM-derived MSCs had similar growth characteristics and
multipotential properties as their ICBMAcounterparts. This is of interest
as MSCs from other adipogenic sources have often been shown to be
inferior to ICBMA in forming bone [12,13] and thismay be related to the
intra-osseous location of MSCs in long-bone cavities.Numerous literature reports describing the presence of CFU-F/
MSCs in connective adipose tissues, including lipoaspirates, document
MSC frequencies that are considerably higher than in BM aspirates (at
least 2 orders of magnitude) (reviewed in [44]). In comparison, the
abundance ofMSCs in “yellow” fattymarrow aspirates observed in our
study appears to be relatively minor (only a 2–5 fold higher than in
classical “red” marrow aspirates). Given the unique function of
adipocytes in the marrow [45–47] and the different metabolic
functions of fat in different depot sites [47], our data indicate that
the MSC pool size in “fatty tissues” is clearly site-speciﬁc. Variations in
MSC function have been documented for different types of bone:
orofacial, axial and appendicular [48] and different depots of fat: arm,
ﬂank, thigh and abdomen [49]. The heterogeneity of MSCs resident
within seemingly the same type of tissues but located in different
anatomical areasmay be explained by varying local demands for tissue
turnover andmechanical loads [48]. Additionally, theMSC topography
in diverse human tissues has been described as primarily perivascular
[50,51] and it is possible that the lowerMSC frequency in fattymarrow
as opposed to subcutaneous fat may be also related to blood vessel
density as suggested previously for human synovium [52] and equine
adipose tissue [53].
The fact that LBFBM-derived cultured MSCs were able to effectively
differentiate towards osteoblasts and chondrocytes in vitro provided
strong evidence that minimally expanded LBFBM-derived MSCs can be
usedas cell therapy for fracturenon-unions. Furthermore, highnumbers
of CD45−/lowCD271+ cells present in LBFBM samples (up to 67,000,
median 43,620 in 10 ml) suggested that their direct injection, in a one-
stage procedure, may be possible without prior cell-culture. One
previous study has showed that a dose of 50,000 uncultured MSCs
from ~300 ml of ICBMA was efﬁcacious following injection into non-
union fracture sites [10]. A lower volume of LBFBMwould therefore be
sufﬁcient to obtain a similar number ofMSCs. UnculturedMSCs could be
effectively concentrated using magnetic beads against the CD271
molecule, based on our ﬁndings showing that the proportions of
CD45−/low CD271+ cells closely reﬂected that of CFU-Fs [28].
The ﬁndings from this study also offer an additional cellular
mechanism to explain the efﬁcient bone healing process following LB
fracture. They show, for the ﬁrst time, that the marrow contents of long
bones contain largenumbersof functionally-competent localMSCs.Given
a novel concept of local MSC recruitment to fracture sites [54,55] and our
ﬁndings showing large numbers of MSCs in LBFBM in humans, our data
point towards a potentiallymajor contributionof locally-recruited LBFBM
MSCs to healing of long bone fractures. Systemic MSC circulation in
healthy humans and in response to injury remains poorly understood
[56–60], and in this respect our ﬁndings showing no circulating MSCs in
patientswith fracturenon-union (despitehighMSCnumbers in ICBMand
LBFBM) are noteworthy. To the best of our knowledge, the enumeration
and the ‘ex vivo’ phenotype of MSCs in LBFBM in comparison to donor-
matched ICBMA have never been reported before. Furthermore, we
showed that the marrow contents of long bones contained normal
amounts of other cells with regenerative potential (CD34+ and CD31+
cells [61,62]) necessary to orchestrate the fracture healing processes.
In summary, this study demonstrates that the femoral IM cavity
represents a depot of MSCs which could be used for autogenous/
allogeneic use and can be harvested using ‘low-tech’ techniques for a
variety of commonlyperformedoperations including trauma surgery and
total hip replacement. The IM cavities of long-bones, in which the FBM
resides, are also readily accessible by the orthopaedic surgeon during
lower-limb arthroplasty/nailing of long-bone fractures, with themarrow
contents requiring removal prior to prosthesis insertion. Enumeration of
MSCs from LBFBM is possible using the CD271+ CD45low phenotype and
their concentration could be achieved with the use of magnetic beads
against the CD271 molecule. The use of freshly-isolated or minimally-
expanded LBFBM-derivedMSCs could thereforehave important scientiﬁc
and economic beneﬁts in tissue engineering and treatment of fracture
non-unions.
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